Ocera Therapeutics fka OCRX

[longx]

Do you think Mallinckrodt would gamble $42Mil only not to see the 1st & 2nd milestones? And these two milestones should be easily achievable within 18 months as it's simply the enrollment of the first patient in a Phase 3 Clinical Trial. For detailed info on this, please search for the text “IV Milestone” and "“Oral Milestone” in the following merger agreement document:
https://www.sec.gov/Archives/edgar/data/1274644/000119312517330223/d487980dex21.htm
The 3rd milestone is very difficult to achieve (probability of success is less than 5%), but by that time Mallinckrodt already spent $67M (= $42M + $10M + $15M), and I hope they had already studied the clinical data from the first two phases carefully and not to gamble $67Mil to see OCR-002 failed in phase 3.
Anyway I'm into this mainly for the 1st & 2nd milestone payments.